Last mentioned: Feb 26, 2026
Commercial Ramp-Up
Targeted date for full-scale commercial isotope production and revenue growth.
QLE Spin-Off Planning
Strategic restructuring to separate enrichment tech from product verticals.
Emerging Growth Conference
CEO Paul Mann provides update on isotope production and 2026 strategy.
Silicon-28 Shipments
First shipments of high-purity Silicon-28 sent to semiconductor customers.
QLE Spin-off Completion
Formal separation of the Quantum Leap Energy subsidiary into a standalone entity.
Commercial Ramp-up
Full-scale commercial production across medical and industrial isotope lines.
Silicon-28 Shipments
Initial shipments of high-purity Silicon-28 to semiconductor partners.
ASP Isotopes CEO Paul Mann has outlined a 2026 commercialization roadmap, highlighting imminent Silicon-28 shipments for the semiconductor industry and a strategic spin-off of its Quantum Laser Enrichment (QLE) division. The transition marks a shift from R&D to high-value industrial production across the semiconductor, medical, and nuclear sectors.
ASP Isotopes CEO Paul Mann announced a 2026 commercialization ramp-up, highlighted by the upcoming shipment of Silicon-28 and the strategic spin-off of its Quantum Leap Energy (QLE) subsidiary. The move signals a transition from a pre-commercial advanced materials firm to a revenue-generating producer of medical and industrial isotopes.
ASP Isotopes CEO Paul Mann outlined a strategic transition to a 2026 commercial ramp-up, highlighting progress in Silicon-28 shipments and a planned spin-off of its Quantum Laser Enrichment division. The company aims to address critical global shortages in medical isotopes and advanced materials for the semiconductor and nuclear sectors.